Fourth-quarter 2019 revenue estimated to be approximately $23.7 million Full-year 2019 revenue estimated to be approximately $73 million , representing year-over-year growth of more than 220% Flexion provides 2020 product revenue guidance of $120 million to $135 million BURLINGTON, Mass. , Jan.
BURLINGTON, Mass. , Jan. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of an aggregate of 17,000 stock options and 2,800 restricted stock units. The Compensation Committee of the Board of Directors
Conference call scheduled for Friday, December 27, 2019 at 8:00 a.m. ET BURLINGTON, Mass. , Dec. 26, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update
BURLINGTON, Mass. , Dec. 17, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the first three patients were enrolled in a clinical trial to evaluate the efficacy of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with
BURLINGTON, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Neil Bodick, M.D., Ph.D., Chief Scientific Officer, will retire effective January 3, 2020 . Dr. Bodick co-founded Flexion in 2007 with Michael Clayman, M.D., the company’s President
NFL broadcaster Solomon Wilcots to go “Knee to Knee” as moderator of discussion with 1980 USA hockey team captain Mike Eruzione, NFL Hall of Fame member Rod Woodson and retired MLB player Chris Dickerson Orthopaedic Summit is the premier gathering of sports medicine and arthroscopic orthopedists
BURLINGTON, Mass. , Dec. 06, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of an aggregate of 25,300 stock options and 4,150 restricted stock units. The Compensation Committee of the Board of Directors
Post-hoc sensitivity analysis assessed efficacy in patients who reported moderate-to-severe osteoarthritis (OA) pain prior to treatment on both ADP and WOMAC-A scales In this analysis of concordant pain reporters, ZILRETTA provided durable pain relief that was statistically significant and
Company reported ZILRETTA ® (triamcinolone acetonide extended-release injectable suspension) net sales of $21.8 million in Q3 representing 29% growth over Q2 Full-year 2019 ZILRETTA net sales guidance range tightened to $70 million to $75 million Flexion initiated Phase 2 trial investigating
BURLINGTON, Mass. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of an aggregate of 14,700 stock options and 2,500 restricted stock units. The Compensation Committee of the Board of Directors
